Q-omics provides the consensus-scored MTND3P23 profile across patient tissues and cancer cell-line models. MTND3P23 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTND3P23 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, MTND3P23 RNA expression shows 6,373 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where MTND3P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND3P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND3P23 survival associations across molecular data types. MTND3P23 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND3P23 RNA expression–survival associations across cancer types. High MTND3P23 expression shows unfavorable associations in KIRC, THCA and LUSC, but favorable associations in SARC, LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTND3P23 RNA expression.
This table summarizes MTND3P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTND3P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND3P23 shows lower tumor expression in THCA and PAAD and higher tumor expression in COAD. The THCA box plot shows higher MTND3P23 RNA expression in normal versus tumor tissue (log2 FC = −0.126, t-test p < 0.001).
This table shows molecular features associated with MTND3P23 in patient tissues and cancer cell lines. In patient samples, MTND3P23 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
